The Hindu Business Line : Ranbaxy makes 3 fresh ARV filings to WHO

This comes shortly after the company announced that it had begun filing data for its range of ARVs with the US FDA under its expedited review process for the US President's Emergency Programme For AIDS Relief (PEPFAR).

Ranbaxy's anti-AIDS drugs were dropped from the WHO list last year.

In a statement, Dr Brian W. Tempest, Chief Executive Officer and Managing Director, Ranbaxy, said, "Ranbaxy fully supports WHO's pre-qualification project and we are working speedily to provide adequate fresh data to the WHO on our generic ARVs, including fixed dose combinations, so that they can study it and provide their expeditious approvals. This will pave the way for the early availability of these quality medicines, in areas where they are most urgently needed."

Ranbaxy's facilities at Paonta Sahib in Himachal Pradesh(that will also manufacture these ARVs) were inspected recently by the USFDA.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Phillips Carbon Black's eco protection

Ranbaxy makes 3 fresh ARV filings to WHO

Cox & Kings eyes hotel properties

Korean FDA nod for Bharat Biotech's vaccine facility

Dredging Corp plans interim dividend

Vybra Automet board okays pref offer

Lukewarm response to Actis' offer for Swaraj Mazda stake

Century Textiles to expand paper and denim units

Mangalore Chemicals to set up met coke unit — Shriram group taking 45 pc in new entity

Keltron staff on `relay strike'

ICRA signs pact with Turkish rating agency

Murugappa group offer to fishermen hit by tsunami

Bengal Immunity liquidation case deferred

Premier Auto unveils 2-tonner pick-up vehicle